Loria-Rebolledo LE, Watson V, Hassan S, Gabbay M, Tahir N, Hossain M, Goodall M, Frith L. Public contributors' preferences for the organization of remote public involvement meetings in health and social care: a discrete choice experiment study. Health Expect. 2023 Feb;26(1):146-59. doi: 10.1111/hex.13641
Lennon RP, Zgierska AE, Miller EL, Snyder B, Keshaviah A, Hu XC, Zhou H, Van Scoy LJ. Lower intent to comply with COVID-19 public health recommendations correlates to higher disease burden in following 30 days. South Med J. 2021 Dec;114(12):744-50. doi: 10.14423/SMJ.0000000000001332
Lennon RP, Miller EL, Dong H, Rabago D, Zgierska A. Association of the US COVID-19 pandemic and attenuated influenza detection. South Med J. 2021 Jun;114(6):343. doi: 10.14423/SMJ.0000000000001254
Cunningham NA, Abhyankar P, Cowie J, Galinksy J, Methven K. Regenerative medicine: stroke survivor and carer views and motivations towards a proposed stem cell clinical trial using placebo neurosurgery. Health Expect. 2018 Feb;21(1):367-78. doi: 10.1111/hex.12632
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Bullard JT, Eberth JM, Arrington AK, Adams SA, Cheng X, Salloum RG. Timeliness of treatment initiation and associated survival following diagnosis of non-small-cell lung cancer in South Carolina. South Med J. 2017 Feb;110(2):107-13. doi: 10.14423/SMJ.0000000000000601
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.
Garcia-Albeniz X, Martinez-Fernandez A, Gascon P. Combining targeted therapies. Target Oncol. 2007 Oct;2(4):241-52. doi: 10.1007/s11523-007-0062-5
Cheraghi-Sohi S, Bower P, Mead N, McDonald R, Whalley D, Roland M. What are the key attributes of primary care for patients? Building a conceptual 'map' of patient preferences. Health Expect. 2006 Sep 1;9(3):275-84.